Floatz logo

Setmelanotide

Morbid Obesity

Rhythm Pharmaceuticals, Inc.protein_peptidePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

66 Active assets in the Morbid Obesity cohort.

Asset / SponsorPhaseRating
LIDOCAINE
Instituto Mexicano del Seguro Social
Phase 4BBB
Colesevelam
Hvidovre University Hospital
Phase 4BBB
Chenodeoxycholic Acid
Hvidovre University Hospital
Phase 4BBB
PROPOFOL
G.Gennimatas General Hospital
Phase 4BBB
RAMIFENTANYL
Hospital dos Lusíadas
Phase 4BBB

View all 50 →

Same molecule, other indications

Setmelanotide is also rated in:

Bardet-Biedl syndromeDormant
A
Indicative ·
81 / 100
View asset →
Alstrom syndromeDormant
BBB
Indicative ·
75 / 100
View asset →
inherited obesityDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →